A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia
Romiplostim and eltrombopag, the first thrombopoietic receptor-agonists with demonstrated efficacy against immune thrombocytopenia in prospective controlled studies, were recently authorized in most countries for adults with chronic immune thrombocytopenia. So far, no data are available about the po...
| Päätekijät: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
Ferrata Storti Foundation
2013-06-01
|
| Sarja: | Haematologica |
| Linkit: | https://haematologica.org/article/view/6688 |